These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32404952)

  • 1. Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.
    Tang Z; Toruner GA; Tang G; Cameron Yin C; Wang W; Hu S; Thakral B; Wang SA; Miranda RN; Khoury JD; Medeiros LJ
    Mod Pathol; 2020 Oct; 33(10):2035-2045. PubMed ID: 32404952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
    Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
    Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of bcr/abl fusion gene and its derivative chromosome 9 deletions in CML by using home-made bcr/abl extra-signal probe].
    Lai YY; Feng L; Wang Z; Lü S; Dang H; Shi Y; He Q; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):199-203. PubMed ID: 20137147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
    Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
    BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia.
    Bi X; Li C; Shang M; Han B; Li H; Sun L; Lin Y; Yang S
    J Hematop; 2024 Jun; 17(2):97-101. PubMed ID: 38492169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
    May PC; Reid AG; Robinson ME; Khorashad JS; Milojkovic D; Claudiani S; ; Willis F; Apperley JF; Innes AJ
    BMC Med Genomics; 2023 Jul; 16(1):172. PubMed ID: 37496024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis and identification of variant Ph chromosome translocation in patients with chronic myelogenous leukemia by conventional cytogenetics and fluorescence in situ hybridization].
    Liu XP; Liu SH; Li CW; Bo LJ; Qin S; Dai Y; Qian LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):298-303. PubMed ID: 15228654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Nair JKKM; Sreedharan H
    J Environ Pathol Toxicol Oncol; 2018; 37(2):117-126. PubMed ID: 30055547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
    Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
    Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Kearney HM; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP
    Hum Pathol; 2019 Jul; 89():109-114. PubMed ID: 30267776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.
    Manda-Mapalo MT; Khalili P; Quintana D; Rabinowitz I; Zhang QY
    Cancer Genet; 2016 Oct; 209(10):481-485. PubMed ID: 27810077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals.
    Abou Mourad YR; Bhargava R; Bruyère H; Gillian T; Barnett MJ; Forrest DL; Nevill TJ; Toze CL; Nantel SH; Shepherd JD
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):281-6. PubMed ID: 23098889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.
    Morris CM
    Methods Mol Biol; 2011; 730():33-61. PubMed ID: 21431633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.